PRIMARY MYELOFIBROSIS (PMF)
Clinical trials for PRIMARY MYELOFIBROSIS (PMF) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MYELOFIBROSIS (PMF) trials appear
Sign up with your email to follow new studies for PRIMARY MYELOFIBROSIS (PMF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare bone marrow cancer: drug duo targets spleen swelling and fatigue
Disease control Recruiting nowThis phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for adults with myelofibrosis, a rare bone marrow cancer. The study enrolls 460 people who have not taken JAK inhibitors before. The main goals are to shrink th…
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 10:56 UTC
-
New hope for rare bone marrow cancer: drug combo trial launches
Disease control Recruiting nowThis early-stage study tests whether adding pelabresib to the standard drug ruxolitinib is safe for Japanese adults with myelofibrosis, a rare bone marrow cancer. Only 6 participants will receive the combination to check for side effects and measure drug levels. The goal is to fi…
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 10:35 UTC
-
New hope for rare blood cancers: first human trial of PRT12396 begins
Disease control Recruiting nowThis early-stage study tests a new drug called PRT12396 in about 100 people with two rare blood cancers: polycythemia vera and myelofibrosis. The main goals are to find a safe dose and see if the drug can help control the disease. Participants must have a specific genetic mutatio…
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Desperate patients get early access to promising drug for multiple Life-Threatening conditions
Disease control AVAILABLEThis program offers early access to the drug ruxolitinib (INC424) for patients with serious or life-threatening conditions like myelofibrosis, severe COVID-19, and graft-versus-host disease who have no other treatment options. It is for people who cannot join a clinical trial and…
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study is a long-term registry for people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, surveys, and insurance data from 5,000 participants over at least five years to understand how the disease progresses an…
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 26, 2026 11:04 UTC
-
Scientists hunt for immune clues to beat rare blood cancers
Knowledge-focused Recruiting nowThis study looks at how the immune system responds to myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect blood and bone marrow samples from 150 adults with MPN and healthy volunteers to find immune cells that recognize cancer cells. The g…
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Sponsor: Université Catholique de Louvain • Aim: Knowledge-focused
Last updated May 26, 2026 10:51 UTC